Urothelial Cancer

The FDA approved mitomycin intravesical solution for recurrnet, low-grade, intermediate-risk non–muscle-invasive bladder cancer.

First-line enfortumab vedotin plus pembrolizumab continued to demonstrate efficacy across subgroups of locally advanced or metastatic urothelial carcinoma.

A deep dive into the phase 3b ABLE-32 trial reveals the need for more treatments for patients with intermediate-risk NMIBC.

UGN-102 showed strong responses in patients with recurrent, intermediate-risk, low-grade non–muscle-invasive bladder cancer, per the phase 3 ENVISION trial.

Bogdana Schmidt, MD, MPH, discusses the role of minimally invasive and robotic strategies for the treatment of patients with bladder cancer.

The photosensitizing drug and light delivery system yielded complete responses and a low rate of disease recurrence in patients with low-grade UTUC.

Perioperative sacituzumab govitecan-hziy plus pembrolizumab was safe and active in muscle-invasive bladder cancer.

BCG plus mitomycin may represent good alternative to BCG alone in NMIBC.

Nivolumab plus ipilimumab failed to improve overall survival in cisplatin-ineligible, unresectable urothelial carcinoma.

Sasanlimab plus BCG led to a PFS benefit vs BCG alone in patients with CIS and T1 high-risk non–muscle invasive bladder cancer.

Read a recap of the episodes of OncLive On Air that debuted in May 2025.

Dr Galsky discusses the FDA approval of neoadjuvant durvalumab plus chemotherapy followed by adjuvant durvalumab monotherapy for MIBC.

CHMP backed perioperative durvalumab plus neoadjuvant chemotherapy for MIBC based on the NIAGARA trial, which showed improved EFS vs chemotherapy alone.

FDA’s ODAC voted on therapeutic approaches in lymphoma, bladder, prostate, and myeloma, and more from OncLive this week.

The FDA’s ODAC voted against the risk/benefit profile of UGN-102 for recurrent, low-grade, intermediate-risk non–muscle-invasive bladder cancer.

Bogdana Schmidt, MD, MPH, discussed FDA-approved BCG-refractory treatments and recent shifts in BCG-naive NMIBC management.

Matthew Galsky, MD, discusses the significance of the FDA approval of neoadjuvant durvalumab plus chemotherapy followed by adjuvant durvalumab in MIBC.

Evangelia Vlachou, MD, discusses the investigation of enfortumab vedotin plus pembrolizumab as perioperative therapy in upper tract urothelial cancer.

Bogdana Schmidt, MD, MPH, details the emergence of novel treatment delivery methods in bladder cancer.

Bogdana Schmidt, MD, MPH, details the role of BCG in bladder cancer and navigating BCG shortages across the board during Bladder Cancer Awareness Month.

Disitamab vedotin plus toripalimab improved PFS and OS vs chemotherapy in HER2-expressing metastatic urothelial carcinoma.

A doublet is approved for KRAS-mutated ovarian cancer, T-DXd followed by THP improves pCR rates in HER2+ breast cancer, and more from OncLive.

Durvalumab plus BCG induction and maintenance improved DFS vs BCG in these settings alone in patients with high-risk non–muscle-invasive bladder cancer.

Petros Grivas, MD, PhD, details questions and considerations for integrating perioperative durvalumab plus neoadjuvant chemotherapy into MIBC management.

Petros Grivas, MD, PhD, discusses data from CheckMate 274 and how emerging data from bladder cancer trials are shaping immunotherapy strategies in MIBC.